Jennifer Moses
About Jennifer K. Moses
Independent Class II director at Viridian Therapeutics (VRDN), serving since July 2021; age 50 as of April 25, 2025. She is Chief Financial Officer of Investors Management Corporation (since April 2023), with prior experience as CFO and VP Finance & Accounting at G1 Therapeutics, earlier partner roles at Rankin McKenzie, and formative experience at Deloitte; B.S. in Accounting (Penn State) and a C.P.A. She chairs the Audit Committee, serves on the Compensation Committee, and has been designated an SEC “audit committee financial expert.”
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| G1 Therapeutics, Inc. (Nasdaq: GTHX) | Chief Financial Officer | May 2019 – Apr 2023 | Biopharma CFO with public-company reporting and capital markets exposure |
| G1 Therapeutics, Inc. | VP, Finance & Accounting | Mar 2015 – May 2019 | Built finance function ahead of CFO role |
| Rankin McKenzie, LLC | Partner (Acting CFO/Controller for venture-backed companies) | Oct 2007 – Feb 2015 | Portfolio of operating finance mandates |
| Deloitte & Touche LLP / Deloitte Tax LLP | Tax services; later strategic planning/internal communications in Office of CEO of Deloitte Tax LLP | (Pre-2007; dates not specified) | Big Four training; strategic exposure |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Investors Management Corporation (IMC) | Chief Financial Officer | Apr 2023 – present | Private holding company finance leadership |
- No current public company directorships disclosed for Ms. Moses.
Board Governance
| Committee | Role | 2024 Meetings | Independence/Notes |
|---|---|---|---|
| Audit Committee | Chair | 4 | Independent; designated “audit committee financial expert” |
| Compensation Committee | Member | 4 | Independent |
- Classified board: Ms. Moses is a Class II director; term expires at the 2026 Annual Meeting; age 50.
- Board met 10 times in 2024; each then-current director attended at least 75% of Board/committee meetings served.
- Risk oversight: Audit oversees major financial, IT/cyber, and compliance risks; Compensation monitors risk in pay programs; Nominating oversees governance effectiveness.
- Overboarding policy: limit of five public-company boards for non-executive directors; all current directors in compliance.
- Compensation Committee retains independent advisors; in 2024, transitioned from Radford to Compensia; Committee determined no consultant conflicts of interest.
- Compensation Committee interlocks and insider participation: none disclosed.
Fixed Compensation
Director cash compensation policy (FY2024 terms):
| Component | Amount ($) |
|---|---|
| Annual cash retainer (non-employee directors) | 40,000 |
| Board chair additional retainer | 30,000; increased to 32,500 effective 1/1/2025 |
| Audit Committee – member / chair | 10,000 / 20,000 |
| Compensation Committee – member / chair | 7,500 / 15,000 |
| Nominating Committee – member / chair | 5,000 / 10,000 |
| Science Committee – member / chair | 7,500 / 15,000 |
2024 actual non-employee director compensation – Jennifer K. Moses:
| Metric | 2024 Amount ($) |
|---|---|
| Fees earned or paid in cash | 67,357 |
| Option awards (grant-date fair value) | 185,307 |
| Total | 252,664 |
Interpretation: Cash + committee roles approximate policy levels for an Audit Chair (20,000) plus Compensation member (7,500) on top of the 40,000 retainer, with small proration effects reflected in the actual $67,357 cash; equity constituted the majority of 2024 compensation.
Performance Compensation
Director equity program terms:
| Program | Grant Size | Exercise Price | Vesting |
|---|---|---|---|
| Initial grant upon appointment (2024 policy) | 42,000 options | Fair market value on grant date | 36 equal monthly installments (time-based) |
| Annual grant upon re-election | 21,000 options | Fair market value on grant date | Vests in full on earlier of one-year anniversary or next annual meeting (time-based) |
2024 equity awards & holdings – Jennifer K. Moses:
| Metric | Amount |
|---|---|
| Option awards – grant-date fair value (2024) | 185,307 |
| Options held as of 12/31/2024 | 78,500 |
| Options exercisable within 60 days of 3/31/2025 (included in beneficial ownership) | 57,500 |
- Director equity is time-based (no performance metric linkage for directors).
Other Directorships & Interlocks
| Company | Role | Committee Roles | Notes |
|---|---|---|---|
| — | — | — | No current public company directorships disclosed for Ms. Moses |
- Compensation Committee interlocks: none disclosed.
Expertise & Qualifications
- Financial expert; Board determined Ms. Moses qualifies as an “audit committee financial expert.”
- Deep public-company CFO experience in biopharma (G1 Therapeutics).
- Current finance leadership at a diversified private holding company (IMC).
- B.S. in Accounting (Penn State), Certified Public Accountant.
Equity Ownership
| Holder | Shares Beneficially Owned | % Ownership | Notes |
|---|---|---|---|
| Jennifer K. Moses | 57,500 | <1% | Beneficial ownership as of 3/31/2025; consists of shares underlying options exercisable within 60 days (per footnote (6)). Company had 81,589,427 shares outstanding at that date. |
- As of 12/31/2024, Ms. Moses held 78,500 options.
- Anti-hedging policy prohibits short-term trading, short sales, derivatives (puts/calls), and hedging by directors and Section 16 officers.
- No disclosure of share pledging by Ms. Moses.
- Section 16(a) compliance: all directors and officers filed timely reports in 2024.
Governance Assessment
-
Strengths
- Audit Committee Chair with SEC-designated financial expert status—strong oversight of financial reporting, auditor independence, and related-party review.
- Independent director; Board affirms committee independence across all members.
- Attendance: Board met 10 times in 2024; each director attended at least 75% of meetings—acceptable engagement baseline.
- Pay alignment: director compensation dominated by equity options with time-based vesting; annual re-election grant structure aids alignment with shareholder outcomes.
- Process safeguards: independent compensation consultants (Radford, then Compensia) with no conflicts; robust related-person transaction policy; anti-hedging policy; overboarding limits in place and met.
- Plan guardrails: annual cap of $500,000 in total director compensation (cash + equity grant-date value), $1,000,000 in initial appointment year; prohibition on option repricing without prior stockholder approval.
-
Potential risks/considerations
- Company-level related-party exposure via Paragon agreements (linked to significant stockholder Fairmount and its affiliates); however, transactions disclosed as arm’s-length and fall under Audit Committee oversight (chaired by Ms. Moses). Not a Moses-specific conflict disclosed.
- Ownership stake is modest (<1%), typical for small-cap biotech directors; incentives primarily via options rather than stock ownership guidelines (no director ownership guideline disclosed).
-
RED FLAGS
- None specific to Ms. Moses disclosed (no interlocks, no delinquent filings, no pledging, no personal related-party transactions reported).